Drug Profile
Research programme: small-molecule nucleic acid therapeutics - F-star Therapeutics
Alternative Names: SB 11177; SB 11179Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Spring Bank Pharmaceuticals
- Developer F-star Therapeutics; National Institute of Allergy and Infectious Diseases; Spring Bank Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antivirals; Immunotherapies; Nucleic acids; Small molecules
- Mechanism of Action Cyclic AMP phosphodiesterase inhibitors; Immunosuppressants; MPYS protein stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Cancer; Solid tumours
- Discontinued Asthma; Chronic obstructive pulmonary disease; Hypersensitivity; Inflammation
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural)
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 28 Jul 2021 No recent reports of development identified for preclinical development in Cancer in USA (Intraperitoneal)